

**PRODUCT INFORMATION**

|   |   |
|---|---|
| <b>Clone ID</b>                         | 1H6   |
| <b>Target</b>                           | CL2A  |
| <b>Synonyms</b>                         | N.A.  |
| <b>Host Species</b>                     | Rabbit  |
| <b>Description</b>                      | Anti-CL2A(ADC linker) antibody(1H6); Rabbit mAb   |
| <b>Delivery</b>                         | In Stock  |
| <b>Uniprot ID</b>                       | N.A.  |
| <b>IgG type</b>                         | Rabbit IgG  |
| <b>Clonality</b>                        | Monoclonal  |
| <b>Reactivity</b>                       | N.A.  |
| <b>Applications</b>                     | ELISA   |
| <b>Recommended Dilutions</b>            | ELISA 1:5000-10000  |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography   |
| <b>Formulation &amp; Reconstitution</b> | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.  |
| <b>Storage &amp; Shipping</b>           | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.   |
| <b>Background</b>                       | CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types. |
| <b>Usage</b>                            | Research use only   |
| <b>Conjugate</b>                        | Unconjugated  |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.  |



**ELISA assay to evaluate Anti-CL2A Antibody**  
0.2μg Human IgG-CL2A per well




Figure1. Elisa plates were pre-coated with IgG-CL2A (0.2μg/per well). Serial diluted anti-CL2A monoclonal antibody (DME101021) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CL2A monoclonal antibody binding with IgG-CL2A is 4.325ng/ml.

